Cumberland Pharmaceuticals Inc
NASDAQ:CPIX
Intrinsic Value
Cumberland Pharmaceuticals, Inc. is a specialty pharmaceutical company, which engages in the acquisition, development, and commercialization of prescription products. [ Read More ]
The intrinsic value of one CPIX stock under the Base Case scenario is 3.95 USD. Compared to the current market price of 1.68 USD, Cumberland Pharmaceuticals Inc is Undervalued by 57%.
Valuation Backtest
Cumberland Pharmaceuticals Inc
Run backtest to discover the historical profit from buying and selling CPIX stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Revenue Up, Caldolor Expands, Trials Progress
2023-Q3 Earnings Call
In Q3, the company's FDA-approved brands garnered $10.1 million in revenue, bringing the year-to-date total to $30.2 million, with adjusted earnings reaching $4.2 million. Sales of Vibativ increased by 13%, and Kristalose, their leading product, saw an 8% uptick. Caldolor, now approved for infants, and with a new Medicare reimbursement expected in 2025, contributed to an 8% sales increase in its category. Despite challenges, Sancuso's transition is complete and has brought in $12.2 million in cash contributions. The company also emphasized its progress in Phase II clinical trials for ifetroban and the completion of Sancuso's transition to Cumberland's operations. Financial assets stand at $88 million, with an available revolving credit line of up to $25 million, and a share repurchase program has been active.
Balance Sheet Decomposition
Cumberland Pharmaceuticals Inc
Current Assets | 35.7m |
Cash & Short-Term Investments | 18.3m |
Receivables | 9.8m |
Other Current Assets | 7.6m |
Non-Current Assets | 46.1m |
PP&E | 7m |
Intangibles | 23.5m |
Other Non-Current Assets | 15.5m |
Current Liabilities | 28m |
Accounts Payable | 14m |
Accrued Liabilities | 348.1k |
Other Current Liabilities | 13.6m |
Non-Current Liabilities | 24.2m |
Long-Term Debt | 12.8m |
Other Non-Current Liabilities | 11.4m |
Earnings Waterfall
Cumberland Pharmaceuticals Inc
Revenue
|
39.6m
USD
|
Cost of Revenue
|
-6.1m
USD
|
Gross Profit
|
33.5m
USD
|
Operating Expenses
|
-39.7m
USD
|
Operating Income
|
-6.2m
USD
|
Other Expenses
|
-68.5k
USD
|
Net Income
|
-6.3m
USD
|
Free Cash Flow Analysis
Cumberland Pharmaceuticals Inc
What is Free Cash Flow?
CPIX Profitability Score
Profitability Due Diligence
Cumberland Pharmaceuticals Inc's profitability score is 35/100. The higher the profitability score, the more profitable the company is.
Score
Cumberland Pharmaceuticals Inc's profitability score is 35/100. The higher the profitability score, the more profitable the company is.
CPIX Solvency Score
Solvency Due Diligence
Cumberland Pharmaceuticals Inc's solvency score is 37/100. The higher the solvency score, the more solvent the company is.
Score
Cumberland Pharmaceuticals Inc's solvency score is 37/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
CPIX Price Targets Summary
Cumberland Pharmaceuticals Inc
According to Wall Street analysts, the average 1-year price target for CPIX is 8.5 USD .
Ownership
CPIX Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
CPIX Price
Cumberland Pharmaceuticals Inc
Average Annual Return | -9.87% |
Standard Deviation of Annual Returns | 54.42% |
Max Drawdown | -79% |
Market Capitalization | 23.7m USD |
Shares Outstanding | 14 176 500 |
Percentage of Shares Shorted | 0.3% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Cumberland Pharmaceuticals, Inc. is a specialty pharmaceutical company, which engages in the acquisition, development, and commercialization of prescription products. The company is headquartered in Nashville, Tennessee and currently employs 83 full-time employees. The company went IPO on 2009-08-11. Its portfolio of brands includes Acetadote injection, for the treatment of acetaminophen poisoning; Caldolor injection, for the treatment of pain and fever; Kristalose for oral solution, a prescription laxative, for the treatment of constipation; and Omeclamox-Pak for the treatment of Helicobacter pylori (H. pylori) infection and related duodenal ulcer disease. Its brands also include RediTrex injection, for the treatment of active rheumatoid, juvenile idiopathic and severe psoriatic arthritis, as well as disabling psoriasis; Sancuso transdermal system, for the prevention of nausea and vomiting in patients receiving certain types of chemotherapy treatment; Vaprisol injection, to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia; and Vibativ injection.
Contact
IPO
Employees
Officers
The intrinsic value of one CPIX stock under the Base Case scenario is 3.95 USD.
Compared to the current market price of 1.68 USD, Cumberland Pharmaceuticals Inc is Undervalued by 57%.